Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Alemtuzumab in Fludarabine-Refractory CLL
NCT00274976Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Sep 2002
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Sep 2002; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00274976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274976.